A Phase 3 interventional study of GLASSIA in Alpha1-antitrypsin Deficiency, sponsored by Baxalta now part of Shire. Completed at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-14.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 10th largest by enrollment, is one of 5 that started in 2016, is one of 7 in phase 3, and was the 16th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in Denmark
Ages 18–65
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 5 started in 2016.
This study's enrollment of 34 is close to the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 25 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
14 studies in alpha 1-Antitrypsin Deficiency by Takeda: 3 open now, 4 under way, 3 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 14 studies in alpha 1-Antitrypsin Deficiency by Takeda, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2016, is one of 5 in phase 3, and was the 7th registered.
Takeda’s alpha 1-Antitrypsin Deficiency studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, from their registry updates:
Among Takeda’s 14 in alpha 1-Antitrypsin Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is 2-fold: (1) to evaluate the safety and potential immunogenicity of GLASSIA following intravenous (IV) administration via in-line filtration; and (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 milligrams per kilogram (mg/kg) Body weight (BW)/week active alpha1-proteinase inhibitor (A1PI) protein for 25 weeks in participants with emphysema due to congenital A1PI deficiency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female participants meeting the following age criteria:
The participant must have pulmonary function at the time of screening meeting both of the following:
Exclusion Criteria:
Abnormal clinical laboratory results obtained at the time of screening meeting any of the following criteria:
If female, the participant is nursing at the time of screening.
Note: Exclusion criteria #20, #21, #22, #23, and #24 are not applicable to participants who are not required to undergo the bronchoscopy/BAL procedures.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
Biological: GLASSIA
Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
Biological: GLASSIA
Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
Also known as: Alpha1-Proteinase Inhibitor, A1PI
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution
An Adverse Events (AEs) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE. A TEAE that is considered potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution is defined as any embolic or thrombotic event. Number of participants with TEAEs potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution were reported.
Time frame: From start of study treatment up to Week 26
Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion
An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 24 hours (or 1 day where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.
Time frame: From start of study treatment up to 24 hours post infusion
Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion
An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 72 hours (or 3 days where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.
Time frame: From start of study treatment up to 72 hours post infusion
Number of Infusions Discontinued, Slowed, or Interrupted Due to TEAEs
An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Infusions may be interrupted or discontinued in an individual participant in the event of intolerable moderate to severe infusion-related AEs and/or at the discretion of the investigator. Number of infusions that are discontinued, slowed, or interrupted due to TEAEs were reported.
Time frame: From start of study treatment up to Week 26
Number of Participants Who Developed Binding and/or Neutralizing Anti- Alpha1-Proteinase Inhibitor(A1PI) Antibodies
Development of Binding/Neutralizing Anti-A1PI Antibodies=Negative or missing at Baseline and confirmed positive at any post-infusion time point. Participants that had a positive result at Baseline and missing at all post-infusion time points were included as "No Development". Neutralizing anti-A1PI antibodies were only assessed in case of positive binding anti-A1PI antibodies. Anti-A1PI antibodies was detected using validated binding and neutralizing anti-A1PI antibody assays at a qualified immunoassay laboratory. Number of participants who developed binding and/or neutralizing anti-A1PI antibodies were reported.
Time frame: From start of study treatment up to Week 26
Change From Baseline in Antigenic Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid (ELF)
Change from baseline in antigenic A1PI levels in ELF up to Week 14 was reported. Bronchoalveolar Lavage (BAL) procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).
Time frame: Baseline up to Week 14
Change From Baseline in Functional Alpha1-Proteinase Inhibitor(A1PI) Levels in Epithelial Lining Fluid (ELF)
Change from baseline in functional A1PI (also known as Anti-Neutrophil Elastase Capacity \[ANEC\]) levels in ELF up to Week 14 was reported. BAL procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).
Time frame: Baseline up to Week 14
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AEs was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE.
Time frame: From start of study treatment up to Week 26
Number of Participants Who Experienced a Shift From Normal or Clinically Non-significant Abnormal Laboratory Values at Baseline to Clinically Significant Abnormal Laboratory Values at Week 13, 25, and 26
Clinical laboratory values included Hematology (hemoglobin, leukocytes, neutrophils, reticulocytes/erythrocytes \[Ret/Ery\], platelets); Chemistry (sodium, potassium, albumin, alanine aminotransferase \[AA\], aspartate aminotransferase \[ASA\], alkaline phosphatase \[AP\], lactate dehydrogenase \[LD\], gamma glutamyl transferase \[GGT\], bilirubin, direct bilirubin \[DB\], creatinine, creatine kinase \[CK\], glucose); Urinalysis (erythrocytes urine \[EU\], protein urine \[PU\], specific gravity \[SG\], pH) and Immunology (Complement C3, Complement C4). Assessment if a value was normal, clinically non-significant abnormal, or clinically significant abnormal was done by the investigator. Number of participants who experienced a shift from normal or clinically non-significant (NCS) abnormal laboratory values at baseline \[BL\] to clinically significant (CS) abnormal laboratory values at Week 13, 25 and 26 were reported.
Time frame: Baseline, Week 13, 25 and 26
Number of Participants With Treatment-Emergent Seroconversion or Positive Nucleic Acid Test (NAT) for Parvovirus B19 (B19V)
Viral testing for B19V consisted of viral serology or NAT for B19V (Parvovirus B19 IgG Antibody, Parvovirus B19 IgM Antibody, Parvovirus B19 DNA Quant real-time polymerase chain reaction \[RT-PCR\]). Number of participants with treatment-emergent seroconversion or positive NAT for B19V were reported.
Time frame: From start of study treatment up to Week 26
The study was conducted at 21 centers in the United States and 1 center in Canada between 08 Mar 2016 (first participant first visit) and 29 Jul 2020 (last participant last visit).
| Milestone | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Started | 18 | 16 |
| Completed | 17 | 14 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
An Adverse Events (AEs) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE. A TEAE that is considered potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution is defined as any embolic or thrombotic event. Number of participants with TEAEs potentially related to the presence of protein aggregates (particle load) in the GLASSIA solution were reported.
| Participants | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution | 0 | 0 |
An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 24 hours (or 1 day where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.
| Participants | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion | 7 | 3 |
An Treatment-emergent AR and suspected AR was any TEAE which met any of the following criteria: a; A TEAE that began during infusion or within 72 hours (or 3 days where time of onset is not available) following the end of IP infusion, or b; A TEAE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or c; A TEAE for which causality assessment was missing or indeterminate. Number of participants with both treatment-emergent ARs plus suspected ARs were collectively reported.
| Participants | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion | 10 | 7 |
An AE was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Infusions may be interrupted or discontinued in an individual participant in the event of intolerable moderate to severe infusion-related AEs and/or at the discretion of the investigator. Number of infusions that are discontinued, slowed, or interrupted due to TEAEs were reported.
| Number of Infusions | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Number of Infusions Discontinued due to TEAEs | 0 | 0 |
| Number of Infusions Slowed due to TEAEs | 1 | 0 |
| Number of Infusions Interrupted due to TEAEs | 0 | 0 |
Development of Binding/Neutralizing Anti-A1PI Antibodies=Negative or missing at Baseline and confirmed positive at any post-infusion time point. Participants that had a positive result at Baseline and missing at all post-infusion time points were included as "No Development". Neutralizing anti-A1PI antibodies were only assessed in case of positive binding anti-A1PI antibodies. Anti-A1PI antibodies was detected using validated binding and neutralizing anti-A1PI antibody assays at a qualified immunoassay laboratory. Number of participants who developed binding and/or neutralizing anti-A1PI antibodies were reported.
| Participants | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Number of participants with binding Anti-A1PI antibodies | 1 | 1 |
| Number of participants with neutralizing Anti-A1PI antibodies | 1 | 1 |
Change from baseline in antigenic A1PI levels in ELF up to Week 14 was reported. Bronchoalveolar Lavage (BAL) procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).
| Micromolar (mcM) | All GLASSIA 60 mg/kg/Week |
|---|---|
| Change From Baseline in Antigenic Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid (ELF) | 0.515 (0.08 to 2.41) |
Change from baseline in functional A1PI (also known as Anti-Neutrophil Elastase Capacity \[ANEC\]) levels in ELF up to Week 14 was reported. BAL procedures were performed at baseline and on-treatment BAL visit during GLASSIA augmentation therapy. Data for this outcome measure was analyzed and planned to be reported based on overall arm (Arms/Groups were combined as pre-specified in the study protocol).
| mcM | All GLASSIA 60 mg/kg/Week |
|---|---|
| Change From Baseline in Functional Alpha1-Proteinase Inhibitor(A1PI) Levels in Epithelial Lining Fluid (ELF) | 0.256 (-0.28 to 1.54) |
An AEs was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Any AE that occurs on or after the first dose of IP infusion will be considered a TEAE.
| Participants | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 13 | 9 |
Clinical laboratory values included Hematology (hemoglobin, leukocytes, neutrophils, reticulocytes/erythrocytes \[Ret/Ery\], platelets); Chemistry (sodium, potassium, albumin, alanine aminotransferase \[AA\], aspartate aminotransferase \[ASA\], alkaline phosphatase \[AP\], lactate dehydrogenase \[LD\], gamma glutamyl transferase \[GGT\], bilirubin, direct bilirubin \[DB\], creatinine, creatine kinase \[CK\], glucose); Urinalysis (erythrocytes urine \[EU\], protein urine \[PU\], specific gravity \[SG\], pH) and Immunology (Complement C3, Complement C4). Assessment if a value was normal, clinically non-significant abnormal, or clinically significant abnormal was done by the investigator. Number of participants who experienced a shift from normal or clinically non-significant (NCS) abnormal laboratory values at baseline \[BL\] to clinically significant (CS) abnormal laboratory values at Week 13, 25 and 26 were reported.
| Participants | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Hemoglobin: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Hemoglobin: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Hemoglobin: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Hemoglobin: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Hemoglobin: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Hemoglobin: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Leukocytes: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Leukocytes: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Leukocytes: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Leukocytes: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Leukocytes: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Leukocytes: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Neutrophils: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Neutrophils: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Neutrophils: Normal at BL→Abnormal-CS at Week 25 | 1 | 0 |
| Neutrophils: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Neutrophils: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Neutrophils: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Ret/Ery: Normal at BL→Abnormal-CS at Week 13 | 1 | 0 |
| Ret/Ery: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Ret/Ery: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Ret/Ery: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Ret/Ery: Normal at BL→Abnormal-CS at Week 26 | 1 | 0 |
| Ret/Ery: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Platelets: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Platelets: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Platelets: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Platelets: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Platelets: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Platelets: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Sodium: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Sodium: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Sodium: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Sodium: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Sodium: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Sodium: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Potassium: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Potassium: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Potassium: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Potassium: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Potassium: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Potassium: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Albumin: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Albumin: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Albumin: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Albumin: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Albumin: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Albumin: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| AA: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| AA: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| AA: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| AA: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| AA: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| AA: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| ASA: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| ASA: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| ASA: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| ASA: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| ASA: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| ASA: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| AP: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| AP: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| AP: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| AP: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| AP: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| AP: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| LD: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| LD: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| LD: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| LD: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| LD: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| LD: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| GGT: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| GGT: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| GGT: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| GGT: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| GGT: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| GGT: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Bilirubin: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Bilirubin: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Bilirubin: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Bilirubin: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Bilirubin: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Bilirubin: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| DB: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| DB: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| DB: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| DB: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| DB: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| DB: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Creatinine: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Creatinine: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Creatinine: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Creatinine: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Creatinine: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Creatinine: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| CK: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| CK: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| CK: Normal at BL→Abnormal-CS at Week 25 | 1 | 0 |
| CK: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| CK: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| CK: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Glucose: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Glucose: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| Glucose: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Glucose: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| Glucose: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| Glucose: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| EU: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| EU: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| EU: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| EU: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| PU: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| PU: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| PU: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| PU: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| PU: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| PU: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| SG: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| SG: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| SG: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| SG: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| SG: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| SG: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| pH: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| pH: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| pH: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| pH: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| pH: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| pH: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| C3: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| C3: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| C3: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| C3: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| C3: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| C3: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
| C4: Normal at BL→Abnormal-CS at Week 13 | 0 | 0 |
| C4: Abnormal-NCS at BL→Abnormal-CS at Week 13 | 0 | 0 |
| C4: Normal at BL→Abnormal-CS at Week 25 | 0 | 0 |
| C4: Abnormal-NCS at BL→Abnormal-CS at Week 25 | 0 | 0 |
| C4: Normal at BL→Abnormal-CS at Week 26 | 0 | 0 |
| C4: Abnormal-NCS at BL→Abnormal-CS at Week 26 | 0 | 0 |
Viral testing for B19V consisted of viral serology or NAT for B19V (Parvovirus B19 IgG Antibody, Parvovirus B19 IgM Antibody, Parvovirus B19 DNA Quant real-time polymerase chain reaction \[RT-PCR\]). Number of participants with treatment-emergent seroconversion or positive NAT for B19V were reported.
| Participants | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) |
|---|---|---|
| Number of participants with parvovirus B19 IgG antibody | 0 | 1 |
| Number of participants with parvovirus B19 IgM antibody | 0 | 0 |
| Number of participants with Parvovirus B19 DNA Quant RT-PCR | 0 | 0 |
Collected over From start of study treatment up to Week 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GLASSIA (High-end) | 0/18 (0%) | 1/18 (5.6%) | 13/18 (72.2%) |
| GLASSIA (Low-end) | 0/16 (0%) | 1/16 (6.3%) | 9/16 (56.3%) |
| Event | GLASSIA (High-end) | GLASSIA (Low-end) |
|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/18 | 1/16 |
| InfluenzaInfections and infestations | 1/18 | 0/16 |
| PneumoniaInfections and infestations | 1/18 | 0/16 |
| Event | GLASSIA (High-end) | GLASSIA (Low-end) |
|---|---|---|
| NasopharyngitisInfections and infestations | 5/18 | 1/16 |
| Upper respiratory tract infectionInfections and infestations | 0/18 | 3/16 |
| DiarrhoeaGastrointestinal disorders | 3/18 | 0/16 |
| SinusitisInfections and infestations | 0/18 | 2/16 |
| NauseaGastrointestinal disorders | 2/18 | 0/16 |
| VomitingGastrointestinal disorders | 2/18 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 2/18 | 1/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/18 | 0/16 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/18 | 1/16 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/18 | 1/16 |
Safety analysis set consisted of all enrolled participants who received any amount of investigational product (IP), regardless of protocol deviations or non-adherence to study procedures.
| Age, Continuous(Years) | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) | Total |
|---|---|---|---|
| Mean | 57.9 ± 8.95 | 58.9 ± 9.32 | 58.4 ± 9.00 |
| Sex: Female, Male(Participants) | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) | Total |
|---|---|---|---|
| Female | 8 | 6 | 14 |
| Male | 10 | 10 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 17 | 14 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort I: GLASSIA (High-end) | Cohort II: GLASSIA (Low-end) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 18 | 16 | 34 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2016 to primary completion in Jul 2020, 52 months.
Results were first posted in Oct 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency →